Cancer is a genetic disease, a statement which reflects the premise that mutations, stable structural alterations in cellular DNA, play a crucial role in the development of tumours. The suggestion that malignancy is caused by alterations in cellular genetic material is not new (Boveri, 1914) and overwhelming evidence has now accrued in support of the somatic mutation theory of cancer (Bishop, 1987) : Both chemical carcinogens and ionising radiation are mutagenic and the biochemical basis for some of the resultant DNA alterations have been described (Miller, 1978; Storer, 1982) ; some diseases associated with an increased incidence of cancer are characterised by defects in DNA repair mechanisms (Cleaver, 1968; Paterson et al., 1976) , and more recently DNAse I encapsulated in liposomes has been shown to be capable of inducing cellular transformation (ZajacKaye & Tso, 1984) .
In view of the complexity and vast size of the mammalian genome (approximately 3 x 109 base pairs of DNA) it is not surprising that the nature of the genetic targets for tumorigenic mutations remained completely unknown until serendipity gave science a helping hand in the form of the rapidly tumorigenic retroviruses. Members of this retroviral subgroup were known to induce experimental tumours rapidly in vivo and to transform cells in vitro, and the relative simplicity of their genetic structure (approximately 104 base pairs of DNA) made them attractive tools for the dissection of malignancy. With the advent of molecular technology it became apparent that they contain specific viral oncogenes that are responsible for their malignant properties, and furthermore and these viral genes are derived from, and represent a subset of, host cellular genes (proto-oncogenes) present in normal cell DNA (Bishop, 1981) . It is now thought that proto-oncogenes altered by mutational events play an important role in many human tumours, a view that is supported by three main lines of evidence: (a) Certain tumour-specific chromosome translocations appear to result in proto-oncogene activation. The t (8, 14) , t (2, 8) and t (8, 22) translocations associated with Burkitt's lymphoma all seem to result in dysregulation of c-myc expression (Cory, 1986) . In CML the t (9, 22) translocation fuses c-abl to a previously unknown gene (bcr) thereby producing a chimaeric gene the protein product of which has an altered tyrosine kinase activity (Champlin and Golde, 1985 (Stark, 1986) . Furthermore in neuroblastoma and breast cancer amplification of N-myc and neu respectively correlates with tumour stage and provides useful prognostic information (Seeger et al., 1985; Slamon et al., 1987; Editorial, 1987 Parada et al., 1982; Santos et al., 1982; Hall et al., 1983) , in vivo tumorigenicity assays (Fasano et al., 1984) or by direct biochemical methods (Bos et al., 1987) . The evidence that cancer is associated with protooncogene activation is also consistent with the concept of cancer as a multistep process. Thus it has been demonstrated that different activated proto-oncogenes can cooperate in the production of both tumours (Kahn et al., 1986 ) and cell transformation (Land et al., 1983) . Moreover, analysis of the structure and function of the molecules encoded by protooncogenes has shown that many operate as components of normal cellular growth regulatory pathways, as growth factors, growth factor receptors or within the intra-cellular post-receptor pathway (Editorial, 1986) . Such studies have provided dramatic insights into our understanding of the molecular basis of both malignancy and also normal cellular growth and differentiation.
However studies of activated proto-oncogenes tend to provide a rather one-sided view of carcinogenic genetic damage because they concentrate on tumorigenic mutations that produce a functional gene product and which appear to act in a dominant manner. Thus the introduction of an activated proto-oncogene into certain normal cell lines by DNA transfer techniques or as part of a retrovirus, results in the acquisition of readily recognisable malignant characteristics by the recipient cells. By contrast, genes that are ablated by carcinogenic mutations would be much more difficult to detect.
The idea that loss-of-function mutations may play a role in the development of tumours is not new and was first implied by studies of the tumorigenicity of cell hybrids (Harris et al., 1969) together with Knudson's mathematical analysis of retinoblastoma incidence (Knudson, 1971) . Subsequently Ohno (1971) suggested that chromosome loss may play an important role in tumorigenesis and two years later Comings (1973) extended these ideas by postulating that regulatory loci whose products control proto-oncogene expression may act as targets for loss-of-function carcinogenic mutations. Since these early prescient papers considerable evidence has accrued in favour or the concept that gene loss or inactivation plays a crucial role in the genesis of some, and possibly most, tumours. Loss-of-function mutations may promote the neoplastic growth of an affected cell in either an indirect or a direct manner. The genetic defects responsible for xeroderma pigmentosum, ataxia telangiectasia and Bloom's syndrome probably fall into the former category. These inherited conditions are associated with a predisposition to a variety of cancers and are thought to involve germ line inactivating mutations which facilitate tumorigenesis by interfering with DNA repair processes, thus enhancing the accumulation of somatic mutations (Lehman, 1982; Chan et al., 1987; Willis & Lindahl, 1987) . It is conceivable that somatically acquired mutations in DNA repair genes also play a significant role in carcinogenesis and this possibility is consistent with observations that ataxia telangiectasia heterozygotes have an increased incidence of cancer (Swift, 1982; Swift et al., 1987) and that some tumour cells exhibit a reduced ability to repair DNA (Day et al., 1980) . However this review will concentrate on genes in which loss-of-function mutations appear to play a direct role in the neoplastic process. Evidence for their existence stems from studies of two different phenomena: the suppression of malignancy in cell hybrids and the loss or inactivation of specific genes in a wide variety of tumours.
Tumour suppressor genes
It had been realised for many years that fusion of tumorigenic malignant cells to non-malignant cells usually produces non-tumorigenic cell hybrids which subsequently segregate tumorigenic hybrids (Harris et al., 1969; Klein et al., 1971) . Chromosome analysis reveals that the tumorigenic segregants have lost several chromosomes originally present in the nontumorigenic hybrid cells. These results have now been confirmed by extensive studies of rodent and human intraspecies hybrids (Miller & Miller, 1983; Sager, 1985; Stanbridge, 1987) together with rodent x human interspecies hybrids (Klinger, 1982) . The simplest interpretation of these observations is that non-malignant cells contain one or more tumour suppressor genes that are capable of repressing aspects of the malignant phenotype, and which are presumably inactive in, or absent from, malignant cells. Cell hybrids that result from the fusion of appropriate malignant and non-malignant cells are therefore initially non-malignant but may re-express malignant characteristics following the loss of chromosomes carrying tumour suppressor genes.
As a first step towards identifying such genes, numerous investigators have compared the karyotypes of malignant and non-malignant hybrids in attempts to identify specific chromosomes the loss of which is associated with malignancy. Studies of intraspecies rodent cell hybrids have been hampered both by the difficulty of distinguishing the parental origin of chromosomes in the hybrids, and by the random and often rapid loss of chromosomes from the hybrids. As a result several groups have examined human x rodent cell hybrids because chromosome loss is not random (human chromosomes are preferentially lost) and because human and rodent chromosomes can be distinguished. However the rapidity with which human chromosomes are lost still provides a serious obstacle since reexpression of malignancy is usually associated with the loss of multiple chromosomes. It is therefore not surprising that both of these approaches have usually failed to identify specific suppressor chromosomes although there are a few notable exceptions to this (Klinger, 1982; Evans et al., 1982; Stoler & Bouck, 1985) .
Perhaps the most penetrating insights have come from the use of intraspecies human cell hybrids which have been found to exhibit a very stable karyotype. Extensive studies by both Stanbridge and his co-workers and Klinger with his colleagues (Kaelbling & Klinger, 1986) (Saxon et al., 1986) . By contrast fibroblast chromosome 1 has been reported to suppress tumorigenicity of human HT 1080 fibrosarcoma cells , a finding which accords well with the concept that malignancy is a multistep process (Klein & Klein, 1985) .
Gene loss or inactivation in tumours
Recessive mutations at specific loci are implicated in the development of a variety of human and animal tumours (Knudson, 1985) . In Drosophila recessive mutations at more than 20 different loci can result in a variety of tissue-specific tumours (Gateff, 1978; Gatef, 1982) (Anders, 1983; Anders et al., 1985) . The affected genes have been referred to as anti-oncogenes (Green & Wyke, 1985; Knudson, 1985) although this term should not be taken to necessarily imply a direct interaction with oncogenes.
Retinoblastoma and Wilms' tumour are the best studied human malignancies involving recessive mechanisms. Knudson (1971) originally suggested that retinoblastomas result from two sequential mutations and it has subsequently become evident that these affect both alleles of a particular gene; in familial cases the first mutation is inherited, whereas both mutations are somatic in sporadic cases. This explains the apparent paradox whereby predisposition to the tumour may be inherited as an autosomal dominant trait at the level of the whole organism, whilst at the cellular level the neoplastic defect is recessive. This theory has been extended by cytogenetic (Francke, 1976) and linkage (Sparkes et al., 1980) . Wilms' tumour or nephroblastoma also occurs in heritable and sporadic forms and familial cases may be associated with aniridia, genito-urinary abnormalities and mental retardation. Cytogenetic studies of individuals with the heritable form of the disease have revealed an association with constitutional deletions involving band p13 of chromosome 11 (Riccardi et al., 1978; Francke et al., 1979) and similar abnormalities are seen in some tumours from patients with no family history of the disease (Slater, 1986) . In tumours with an apparently normal karyotype, and in cases where no karyotypic data are available, RFLP analysis has confirmed the presence of deletions involving the short arm of chromosome 11 (Fearon et al., during the development of other embryonal tumours . These data are all consistent with the presence of a recessive tumour gene at llpl3. However a simple 'two hit' hypothesis would suggest that maternal and paternal alleles of such a gene would have an equal probability of being affected by each hit. One hint that the mechanisms may not be quite so simple comes from the finding that the maternal chromosome 11 is lost much more frequently than its paternal homologue in sporadic Wilms' tumours (Schroeder et al., 1987) . The explanation for this observation is unclear but may involve differential sensitivity of maternal and paternal gametes to mutations at llpl3 or the presence of a linked transforming gene that is differentially expressed by maternal and paternal copies of chromosome 11 (Wilkins, 1988 
Relationship to proto-oncogenes
The evidence surveyed above suggests that various aspects of the malignant phenotype may result from loss or inactivation of specific cellular genes. However these observations need to be reconciled with the mass of evidence that proto-oncogene activation plays a central role in malignancy. As described above the suppression of HeLa cell tumorigenicity by human fibroblasts has been studied in great detail, but unfortunately virtually nothing is known about the contribution that activated proto-oncogenes make to the malignant properties of HeLa cells. The interaction of tumour suppressor genes with proto-oncogenes has therefore been addressed by studying the suppression of malignant cells known to contain an activated proto-oncogene. Studies of the HT 1080 human fibrosarcoma cell line and the EJ human bladder cell line, which contain an activated N-ras and Ha-ras gene respectively (Hall et al., 1983; Parada et al., 1982) (Craig & Sager, 1985; Griegel et al., 1986) . A different mechanism has been revealed by analysis of untransformed hybrids resulting from the fusion of Rous sarcoma virus-transformed rat fibroblasts (containing the v-src oncogene) to untransformed rodent cell lines. In this system suppression operates by repression of proviral transcription and it has also been shown that the susceptibility of a provirus to suppression is greatly influenced by its cellular integration site (Dyson et al., 1982) . Suppression of RSVinduced transformation may therefore be mediated by a family of negative regulatory genes that control transcription within specific regions of the cellular genome (Green & Wyke, 1985; Wyke & Green, 1986) . Moreover some members of such a family of regulatory genes might be expected to act as targets for carcinogenic recessive mutations (Comings, 1973) .
A third strategy is to look for proto-oncogene expression in tumours known to involve loss or inactivation of specific loci but the results are difficult to interpret. Thus retinoblastomas express high levels of N-myc and as a result it has been suggested that-one function of the Rbl gene is to repress N-myc expression (Lee et al., 1984) . This now seems unlikely since the level of N-myc expression in retinoblastomas, although significantly higher than that found in fibroblasts or normal adult retina, is similar to the level found in normal foetal retina and, furthermore, osteosarcomas that involve inactivation of the Rbl locus do not express high levels of N-myc (Squire et al., 1986 ).
It is apparent that in most instances genes which are tumorigenic by virtue of loss of their function represent a novel family of tumour genes quite distinct from protooncogenes. However the issue is complicated by recent evidence which suggests that some proto-oncogenes may be activated by recessive mutations. Thus several tumours known to contain an activated ras gene have deleted the normal ras allele (Santos et al., 1982; Feinberg et al., 1983; Guerrero et al., 1985) ; studies of mouse skin carcinogenesis have shown that whereas papillomas contain both an activated and a normal Ha-ras allele, progression to invasive carcinoma may be accompanied by loss of the normal allele (Quintanilla et al., 1986) ; and the chromosome carrying an unaltered N-ras allele can suppress tumorigenicity of HT 1080 cells containing an activated N-ras gene (vide supra). These data emphasise that genes which are tumorigenic in a recessive mode may fall into two categories: those that are neoplastic solely by virtue of net loss of their function and proto-oncogenes which exert a neoplastic effect when loss of one allele unmasks an activating mutation in its homologue. (Der et al., 1982; Hall et al., 1983; Fasano et al., 1984) . (Friend et al., 1986; Lee et al., 1987a (Peehl & Stanbridge, 1982 (Mechler et al., 1985; Friend et al., 1986; Lee et al., 1987a) has allowed direct analysis of their protein products. Mutation of the drosophilia 1(2) gl gene is implicated in larval neuroblastomas and imaginal disc tumours. Its protein product localises to the cell membrane and intercellular matrix and its expression during embryonic and larval development correlates with cessation of cellular proliferation suggesting that it may mediate proliferation arrest (Klambt & Schmidt, 1986) . By contrast the retinoblastoma gene product is a nuclear phosphoprotein with DNA binding activity and so may act to regulate other cellular genes (Lee et al., 1 987b) . 3. An increasing number of peptides are known to exhibit differentiation-inducing or growth-inhibiting effects (Roberts et al., 1985; Marx, 1986; Beutler & Cerani, 1987; Gearing et al., 1987) . This hypothesis predicts that the genes encoding such inhibitory factors and their cellular receptors would be prime targets for recessive carcinogenic mutations.
Clinical applications
It is not premature to consider the potential implications of these insights. RFLP analysis has already been used as an approach to ante-natal diagnosis in pedigrees at risk for retinoblastoma (Cavenee et al., 1986; Wiggs et al., 1988) 
